Heavyweight COVID-19 vaccine project settles in Huangpu

A strategic cooperation agreement was signed between Luye Life Sciences Group, GDD Holding Group, and Guangzhou Regenerative Medicine and Health Guangdong Laboratory (Bioland Laboratory) on Aug 12 for COVID-19 vaccine production.

A subsidiary of Luye Life Sciences Group will urgently develop the vaccines needed for clinical use on the Guangzhou International Bio Island, and produce them in a soon-to-be-built base in China-Singapore Guangzhou Knowledge City.

A strategic cooperation agreement is signed between Luye Life Sciences Group, GDD Holding Group, and Bioland Laboratory on Aug 12 for COVID-19 vaccine production.

In addition, the subsidiary will establish three resource-sharing platforms for the vaccine, antibody and molecular diagnosis along with the Bioland Laboratory. The two sides will also cooperate in clinical research and translational medicine research.

With a total investment of 1.2 billion yuan ($185.2 million), the project will offer a one-package medical solution for vaccine R&D, production and clinic experiments. After its up and running, it is expected to generate an annual output value of 8 billion yuan.

Share - WeChat